SATB2 Recombinant Monoclonal Antibody

1. The Autism spectrum disorder candidate genes SATB2, CHD8 and EHMT1 show enriched expression in neurons, especially inhibitory neurons PMID: 29317598
2. up-regulation of miR-31 may underlie endothelial dysfunction in diabetes by targeting Satb2 PMID: 29566115
3. SATB2 as an additional diagnostic marker for the diagnosis of an ovarian manifestation of low-grade appendiceal mucinous neoplasm PMID: 29487003
4. HNF4-alpha and particularly SATB2 may be helpful in the differential diagnosis of pulmonary adenocarcinoma and metastases of colorectal adenocarcinomas PMID: 29243296
5. this study shows that SATB2 is a diagnostic marker of sinonasal intestinal-type adenocarcinoma PMID: 27258560
6. SATB2 could serve as a promising diagnostic biomarker of colorectal cancer metastases. PMID: 29396302
7. SATB2 can be used as a supplementary marker along with CDX2 to identify 'colon-rectum' as the primary site in material from patients presenting with metastasis. PMID: 29924451
8. We describe the phenotype and genotype of 12 individuals with 10 unique (de novo in 11 of 11 tested) pathogenic variants (1 splice site, 5 frameshift, 3 nonsense, and 2 missense) in SATB2 and review all cases reported in the published literature caused by point alterations thus far PMID: 28139846
9. features associated with de novo mutations affecting SATB2 function in individuals ascertained on the basis of intellectual disability PMID: 28151491
10. The mRNA level of SATB2 was lower in tumor tissues than in samples of corresponding unchanged kidney. The results of the presented study suggest the tumor-suppressing function of SATB2. PMID: 29374710
11. MiR-875-5pdirectly binds to the 3'untranslated region of SATB.2 PMID: 29196257
12. These results strongly suggest that SATB2 prevents induction of EMT by suppressing expression of EMT-inducing transcription factors in NSCLC cells. PMID: 27393518
13. We describe here the identification of a de novo SATB2 point mutation in twin boys with cleft soft palate, dental anomalies, and development delay and compare the clinical presentation of SATB2 point mutation patients reported to date. PMID: 28211976
14. our data reveal that SATB2 in alveolar bone mesenchymal stem cells (AB-BMSCs) associates with their age-related properties, and prevents AB-BMSCs senescence via maintaining Nanog expression. PMID: 27632702
15. SATB2 is frequently expressed in appendiceal mucinous neoplasms. In the context of a mucinous neoplasm involving the ovary, any SATB2 positivity should raise the possibility of appendiceal origin. PMID: 26542609
16. our results strongly indicate that the crosstalk between p38 and Akt pathways can determine special AT-rich sequence-binding protein 2 expression and epithelial character of non-small-cell lung carcinoma cells PMID: 28937318
17. SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract. PMID: 28711650
18. we report a exon frameshift mutation in SATB2 in a 15-year-old patient with cleft palate, apparent ID, mild facial dysmorphism, and low weight with additional features of osteoporosis, fractures, progressive tibial bowing, and scoliosis. it provides further evidence of a single-nucleotide, potentially dominant-negative SATB2 allele in association with phenotypes beyond those typically associated with deletion of the gene PMID: 27409069
19. Indicate that beta-catenin and SATB2 are useful immunohistochemical markers for differentiating between pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma. PMID: 28438615
20. SATB2 can directly bind to the regulatory elements in the genetic loci of several stem cell markers and consequently inhibit the progression of CRC by negatively regulating stemness of CRC cells PMID: 27784965
21. miR-599 directly binds to the 3'untranslated region of SATB2, and western blotting showed that miR-599 suppresses the expression of SATB2 at the protein level. This study indicates that miR-599 promotes proliferation and invasion of non-small cell lung cancer cell lines via SATB2. PMID: 28167280
22. SATB2 is a highly sensitive marker for osteosarcomatous differentiation in gynecologic tract PMID: 27294605
23. Although SATB2 immunoexpression helps to distinguish osteosarcoma from their mimickers, the identification of malignant osteoid matrix formation and the integration of clinical and radiological data remain the corner stone of osteosarcoma diagnosis and as yet no antibody has equalled the diagnostic value of this important morphologic hallmark. PMID: 27465835
24. Overexpression of SATB2 repressed the expression of extracellular signal-regulated kinase 5 (ERK5), and activation of ERK5 restored the SATB2-induced inhibition of proliferation and migration in gastric cancer. PMID: 26508023
25. this study shows that SATB2 can be used as an additional marker with similar sensitivity and specificity as CK20 for the diagnosis of Merkel cell carcinoma PMID: 27262585
26. Case Reports: cutaneous osteoblastic osteosarcomas positive for SATB2. PMID: 27043339
27. these results suggest miR-31 inhibited triple negative breast cancer cells migration and invasion through suppressing SATB2 expression. PMID: 27593563
28. SATB2 regulates the mitosis of cell cycle and affects G1 cell cycle via interaction with CDK2. PMID: 26714749
29. Low expression of SATB2 is associated with colorectal cancer. PMID: 26701851
30. Ovarian tumors with mucinous or endometrioid features that express SATB2 are unlikely to be of primary ovarian origin and more likely to be of colorectal/appendiceal origin. PMID: 26551622
31. SATB2 expression increased anchorage-independent growth and cell migration in human bronchial epithelial cells PMID: 26780400
32. Data suggest that MIRN-33a-5p is highly induced by TNFa and BMP-2 in bone marrow stromal cells; anti-osteogenic TNFa down-regulates SATB2 expression indirectly; pro-osteogenic BMP-2 up-regulates SATB2 expression directly. PMID: 26785690
33. SATB2 is a sensitive marker for hindgut well-differentiated neuroendocrine tumors though it is not entirely specific. PMID: 26261600
34. We found that IGFBP6 and SATB2 were significantly down-regulated in HIV-infected CEM*174 cells and 3 different cohorts of HIV/AIDS patients while their promoters were predominantly hyper-methylated compared with normal controls. PMID: 26039376
35. data suggest that SATB2 functions as a tumor suppressor in the development and progression of clear cell renal cell carcinoma PMID: 26097552
36. Immunohistochemical expression of SATB1 and SATB2 was analysed in tissue microarrays with primary tumours and a subset of paired lymph node metastases from 175 patients operated with pancreaticoduodenectomy for periampullary adenocarcinoma. PMID: 25323550
37. SATB2 is a direct target of miR-211. SATB2 expression was upregulated in hepatocellular cancer tissues and cell lines. SATB2 rescued the miR-211-mediated inhibition of cell invasion and proliferation. PMID: 25888635
38. We provide supporting evidence that analysis for deletions or point mutations in SATB2 should be considered in children with intellectual disability and severely impaired speech, cleft or high palate, teeth abnormalities, and osteopenia. PMID: 25885067
39. We here report on a girl with intellectual disability, nearly absent speech and suspected hypodontia who was shown to carry an intragenic SATB2 tandem duplication hypothesized to lead to haploinsufficiency of SATB2. PMID: 25118029
40. Reduced SATB2 dosage leads to mRNA and microRNA expression patterns and DNA methylation patterns more characteristic of differentiating than proliferating neural stem cells. This balance change may underlie neurodevelopmental disorders. PMID: 25966365
41. our data suggest that SATB2 plays an important role in esophageal squamous cell carcinoma progression, and that decreased expression of SATB2 in tumor tissues could be used as a prognostic marker for patients with esophageal squamous cell carcinoma. PMID: 25755730
42. SATB2 as a novel regulator of Osteosarcoma invasion, in part via effects on EPLIN and the cytoskeleton. PMID: 25220418
43. Intragenic duplication--a novel causative mechanism for SATB2-associated syndrome. PMID: 25251319
44. Low SATB2 expression is associated with colorectal cancer. PMID: 25662172
45. SATB2 action is mediated by palladin inhibition and the SATB2/palladin pathway is associated with invadopodia formation in colorectal cancer cells. PMID: 25523619
46. This review will discuss the four major findings regarding SATB1/2 in colorectal cancer studies.[review] PMID: 25543122
47. research showed that miR-182 could directly target the 3'untranslated region (3'UTR) of SATB2 mRNA and subsequently repress both the mRNA and protein expressions of SATB2, which we identified in previous studies as a CRC metastasis-associated protein PMID: 24884732
48. Ectopic expression of SATB2 by transiently transfected with pCAG-SATB2 vector encoding the entire SATB2 coding sequence could reverse the effects of miR-31 on CRC tumorigenesis and progression. PMID: 24386467
49. The application of SATB2 to manipulate stem cells for the reconstruction of bone defects might represent a new approach. PMID: 25200657
50. SATB2 and SOX9 may be acting together via complex cis-regulation to coordinate the growth of the developing jaw. PMID: 24363063

Show More

Hide All

HGNC: 21637

OMIM: 119540

KEGG: hsa:23314

STRING: 9606.ENSP00000260926

UniGene: Hs.516617